Mesoblast (MESO) announced that in connection with the company’s transition to a fully integrated commercial organization it has appointed James O’Brien as its US-based CFO. O’Brien has had global responsibility overseeing corporate and business unit finance, reporting, internal controls and accounting operations at Actavis which subsequently acquired Allergan plc prior to its acquisition by AbbVie (ABBV).
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast Announces Director’s Share Acquisition and New Equity Issuance
- Mesoblast’s Promising Study on Chronic Low Back Pain Treatment: A Market Game Changer?
- Mesoblast Reports Strong Revenue Growth with Ryoncil® Adoption
- Mesoblast reports Q2 Ryoncil revenue up 66% y/y
- Mesoblast receives J-Code for Ryoncil from Medicare & Medicaid Services